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Abstract 
Purpose 
To examine the effects that the sedative and analgesic medications which are 
commonly used in the cardiac catheterisation laboratory have on thermoregulation. 
Design 
A structured review strategy was used. 
Methods 
Medline and CINAHL were searched for published studies and reference lists of 
retrieved studies were scrutinized for further research. Data were extracted using a 
standardised extraction tool. 
Results 
A total of nine studies examined the effect that sedative and analgesic medications 
have on thermoregulation. Midazolam has minimal impact on thermoregulation 
while opioids, dexmedetomidine and propofol markedly decrease vasoconstriction 
and shivering thresholds.  
Conclusions 
Patients who receive sedation in the cardiac catheterisation laboratory may be at 
risk of hypothermia, due to the use of medications that impair thermoregulation. 
Further research is required to identify the prevalence of unplanned hypothermia 
during sedation in the cardiac catheterisation laboratory. 
Keywords: Hypothermia; sedation; cardiac; nursing; thermoregulation. 
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Introduction 
Hypothermia inadvertently occurs in patients undergoing surgical procedures with 
general anaesthesia when the strategies employed to maintain normothermia are 
not sufficient to balance heat production with heat loss. This ‘unplanned’ or 
‘inadvertent’ hypothermia that occurs is a common yet preventable complication in 
the perioperative setting. It has been reported to occur in 50-90% of surgical 
patients.1, 2 Hypothermia is associated with increased risk of major adverse cardiac 
events, wound complications, thrombotic and hemorrhagic complications and 
prolonged hospital stay.3 The cardiac catheterisation laboratory (CCL) is similar to 
the perioperative environment in that there is typically a low ambient room 
temperature and procedures can be of several hours duration. Due to these 
similarities, people undergoing procedures in the CCL may also be at risk of 
hypothermia. However, the majority of procedures performed in the CCL utilise 
procedural sedation and analgesia as opposed to a full general anaesthetic.4 No 
studies, however, have investigated whether or not unplanned hypothermia occurs 
in the CCL setting when sedation is used. In this regard, the aim of this review was to 
examine the effects of the sedative and analgesic medications that are commonly 
used in the cardiac catheterisation laboratory setting on thermoregulation in order 
to provide recommendations for practice and future research regarding the 
prevention of unplanned hypothermia during sedation in the cardiac catheterisation 
laboratory. 
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Background 
Thermoregulation in humans 
In humans, metabolic functions deteriorate when core body temperature 
substantially deviates from normal.3 In response to afferent thermal sensing, the 
hypothalamus triggers both behavioural and autonomic responses in order to 
maintain core body temperature between 36.5 and 37.5 degrees Celsius.5 The 
perception of thermal discomfort, which arises in response to changes in skin surface 
temperature, triggers specific behaviours which help to maintain core temperature 
within the normal range.6 Such behaviours include reducing or increasing skin 
exposure or adjusting the ambient room temperature. In contrast, autonomic 
responses are provoked in response to input from not only the skin surface, but also 
the abdominal and thoracic organs, spinal cord, hypothalamus and other portions of 
the brain.5, 7, 8 Autonomic responses are triggered when the core temperature either 
rises or falls below the interthreshold range, which is just 0.2 degrees Celsius.5 
An increase in core temperature outside of the 0.2 degrees Celsius interthreshold 
range will trigger vasodilation and sweating. In a dry environment, sweating can 
dissipate more heat than is produced from the basal metabolic rate, resulting in a 
net heat loss.2 Vasodilation of the thermoregulatory arterio-venous shunts, which 
are located in fingers and toes, facilitates transfer of heat from the core to the 
surface.5 Small decreases in core temperature outside of the interthreshold range 
will trigger vasoconstriction, which reduces heat loss from convection and skin 
surface radiation.5 Further decreases in the core temperature will provoke shivering. 
Shivering increases body temperature by at least doubling the metabolic rate.2 
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Unplanned perioperative hypothermia 
As normothermia is classified as a core body temperature between 36.5 and 37.5 
degrees Celsius, the exact definition of hypothermia is 36.4 degrees Celsius.5 Of 
note, though, in most clinical studies of unplanned perioperative hypothermia, core 
body temperature below 36 degrees Celsius has been used to diagnose hypothermic 
patients.9 While environmental factors, such as the low ambient room temperature, 
prolonged skin exposure and infusion or irrigation using cold solutions, contribute to 
the development of hypothermia in the perioperative setting, they are not the main 
cause. Healthy volunteers placed in the perioperative environment maintain 
normothermia because their thermoregulatory mechanisms remain intact.9 As such, 
unplanned perioperative hypothermia arises as a direct result of the administration 
of sedative, analgesic and anaesthetic medications that impair normal 
thermoregulatory mechanisms.9 
The administration of sedative, analgesic and anaesthetic medications in the 
perioperative environment may lead to hypothermia due to several mechanisms. 
One mechanism is known as ‘core to peripheral heat redistribution’.9 The 
medications stimulate vasodilation of the thermoregulatory arterio-venous shunts 
which results in a redistribution of heat from the core to the periphery.1 Another 
mechanism by which the administration of sedative, analgesic and anaesthetic 
agents can decrease core body temperature is by decreasing the metabolic rate. 
Studies have shown that anaesthetic agents reduce the metabolic rate by up to 
40%.10 One further mechanism that contributes to the development of unplanned 
perioperative hypothermia is inhibition of autonomic responses to changes in core 
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body temperature. The interthreshold range widens from 0.2 to up to 4 degrees 
Celsius with the administration of anaesthetic agents.11 Consequently, autonomic 
thermoregulation responses, such as vasoconstriction and shivering, will only be 
induced in response to much larger variations in core temperature than usual (Figure 
1).1  
Consequences of unplanned perioperative hypothermia 
Numerous harmful effects have been observed in patients who inadvertently 
develop hypothermia in the perioperative environment. Of particular concern is the 
evidence that indicated morbid cardiac events were more likely to occur in patients 
who became hypothermic.12 In a randomised controlled trial of supplemental 
warming during abdominal, thoracic or vascular surgery, it was found that reduction 
of core body temperature by 1.5°C tripled the rate of major adverse cardiac events.12 
Most patients undergoing procedures in the CCL are already at high risk of such 
complications.13 Hypothermia has also been demonstrated to increase the amount 
of blood loss during surgical procedures due to inhibition of platelet function and 
decreased activation of the clotting cascade.14-16 Bleeding complications are a major 
cause of mortality associated with CCL procedures.17 Hypothermia also reduces the 
metabolism of most medications.18 As a result, duration of post-anaesthetic recovery 
is increased, resulting in increased requirement for healthcare resources.19 Another 
adverse effect of hypothermia is that it induces a sense of thermal discomfort.20 
Hypothermia should be avoided as thermal discomfort has been associated with 
decreased patient satisfaction.21 Some patients report that thermal discomfort is 
worse than pain associated with the surgical procedure.22 These potentially severe 
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consequences of unplanned hypothermia underscore the need for focused 
investigation into its potential occurrence during sedation in the CCL setting.  
Methods 
Design 
A structured review of the literature was undertaken.  
Literature search  
Medline and CINAHL were searched without date restrictions to identify literature 
that addressed the following review questions: 
 Do the sedative and analgesic medications that are commonly used in the 
cardiac catheterisation laboratory setting impair thermoregulation? 
Articles that met the following criteria were included: 
 Empirically derived original research reports; or 
 Systematic reviews of primary research/meta-analyses;  
 Published in peer-reviewed journals; in 
 English language. 
Reference lists of articles that were identified as being relevant to the review topic 
and the grey literature (Google Scholar) were searched to locate studies not 
recognised in the database searches. Search terms, such as ‘hypothermia’, 
‘unplanned hypothermia’, ‘inadvertent hypothermia’, ‘perioperative hypothermia’, 
‘normothermia’, ‘shivering’, ‘piloerection’, ‘body temperature regulation’ and 
‘thermoregulation’ were used. Keywords relevant to the specific sedative and 
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analgesic medications used in the cardiac catheterisation laboratory, such as opioids, 
benzodiazepines, propofol and dexmedetomidine were also used. Titles and 
abstracts were initially screened. Then, all potentially relevant publications were 
retrieved in full-text.  
Data Extraction and Synthesis 
Data was extracted from articles included in the review using a standardised data 
extraction tool designed specifically for this review. Due to the diverse range of study 
designs included in this review, a summary of the results was tabulated and a 
synthesis of results from the included articles is provided in narrative form. 
Results 
A total of nine studies were identified that examined the effect that the sedative and 
analgesic medications, which are commonly used in the CCL, have on 
thermoregulation. A summary of this evidence is provided in Table 1.  
Studies of the effects of sedative and analgesic agents used in the cardiac 
catheterisation laboratory on thermoregulation 
Benzodiazepines  
Only three small studies were identified that reported the effects of benzodiazepines 
on thermoregulation. One of the studies investigated intravenous administration. 
This study reported that midazolam statistically significantly increased the 
interthreshold range from 0.2 +/- 0.1°C to 0.7 +/- 0.3°C (p=0.002).23 It should be 
noted that while statistically significant, this increase in the interthreshold range is 
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far less than the 3-5°C increase associated with anaesthetic agents and may not be 
enough to result in hypothermia.24-26 
The two other studies investigated thermoregulatory effects of intramuscular 
administration of midazolam. In one of the studies, core temperature decreased 
more in patients who received a high dose of intramuscular midazolam (0.075mg/kg) 
compared with low-dose midazolam (0.025mg/kg) and controls, suggesting a dose-
dependent effect on thermoregulation. Thirty minutes after midazolam 
administration, mean core temperature of the high dose group decreased 0.6°C 
compared with 0.3°C for the low dose and 0.1°C for controls (p<0.01).27 The authors 
concluded that the greater decrease in core temperature was due to impaired 
thermoregulatory vasoconstriction, which lead to core to peripheral heat 
redistribution.27 Another study confirmed these findings. A statistically significant 
increase (p<0.05) in peripheral blood flow in people who received midazolam prior 
to induction of a general anaesthetic compared with controls was observed.28  
Opioids 
Two studies were identified that investigated the effect of opioids on 
thermoregulation. Alfentanil administration with doses typically used during general 
anaesthesia produced a statistically significant linear decrease in the 
vasoconstriction (slope = -0.075 +/- 0.067°C/ng-1/mL; r2 = 0.92 +/- 0.07) and shivering 
(slope = -0.063 +/- 0.037°C/ng-1/mL; r2 = 0.98 +/- 0.04) thresholds.29 Meperidine (at 
blood concentration of 1.8 µg/mL) increased the interthreshold range from 0.4 +/- 
0.18°C to 1.9 +/- 0.7°C.30  
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Propofol 
Two studies were identified that investigated the effect of propofol on 
thermoregulation. These studies reported that this medication markedly reduced the 
vasoconstriction (slope = -0.6 +/- 0.1°C/ng-1/mL; r2 = 0.98 +/- 0.02)  and shivering 
(slope = -0.7 +/- 0.1°C/ng-1/mL; r2 = 0.95 +/- 0.05) thresholds.24, 25  
Dexmedetomidine 
One study was identified that investigated the effects of dexmedetomidine on 
thermoregulation.31 The study was a small randomised, double-blind cross-over 
study that involved the administration of a low and a high dose of the medication to 
9 male volunteers. It was reported that dexmedetomidine reduced the 
vasoconstriction threshold by 1.61 ± 0.80°C µg-1mL and reduced the shivering 
threshold by 1.61 ± 0.80°C µg-1mL. The interthreshold range increased to 0.5°C with 
low-dose dexmedetomidine and 1.3°C with high-dose dexmedetomidine. 
Discussion 
Recent surveys of sedation practice in CCLs in the United States, Europe as well as 
Australia and New Zealand indicated that the most common pharmacological agents 
used were benzodiazepines, opioids and the short-acting anaesthetic agent, 
propofol.4, 32, 33 The effects of these medications on thermoregulation were able to 
be identified in this review. 
Midazolam is currently the most commonly used benzodiazepine used for sedation 
in the CCL.4, 32 It is typically administered intravenously as either infusions or bolus 
doses.34, 35 While there has been limited research into the effects of midazolam on 
thermoregulation, the evidence at hand indicates that midazolam does, albeit only 
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to a small degree, impair normal thermoregulation. Also of note, thermoregulation 
becomes more impaired with midazolam administration as the level of sedation 
increases.27 Therefore, the administration of midazolam could potentially contribute 
to the onset of hypothermia in the CCL environment, particularly during procedures 
that require higher doses of sedation.  
Fentanyl is currently the most commonly used opioid analgesic for the induction of 
PSA in the CCL.4, 32 Morphine and meperidine (pethidine) are also used.4, 32, 34 These 
medications are typically administered intravenously. Of note, no studies were 
identified that specifically investigated the effects of fentanyl administration on 
thermoregulation. However, the effect of other opioids, such as meperidine and 
alfentanil, on thermoregulatory response thresholds has been reported.29 While the 
administration of opioids has been associated with impaired thermoregulation, the 
studies were conducted with doses typically used for general anaesthesia, which are 
far greater than that typically used to induce sedation and analgesia during 
procedure performed in the CCL. Also, the effects of these medications on 
thermoregulation seem to be dose-dependent. As such, it is unknown whether the 
doses used during sedation in the CCL setting impair thermoregulation to the extent 
that patients would be at risk of developing hypothermia.    
While not as popular as the benzodiazepine and opiod combination, 
dexmedetomidine is now being utilised for sedation in the CCL setting.33 Moreover, 
reports of the potential utility of dexmedetomidine for sedation during 
electrophysiology procedures have recently emerged.36-38 One study that examined 
the effects of this medication on thermoregulation was identified in this review.31 
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Results indicated that dexmedetomidine does reduce the vasoconstriction and 
shivering thresholds.31  Therefore, patients who receive this medication for sedation 
during procedures performed in the CCL setting may be at risk of becoming 
hypothermic.    
Several recent studies have reported on the safety and effectiveness of using 
propofol for sedation during atrial fibrillation ablation and ICD implant.39-41 Of note, 
though, routine temperature monitoring, before, during or after the procedure, was 
not undertaken as part of these studies.39-41 Surveys of CCL sedation practices have 
also reported that propofol is used.4, 32 The studies included in this review that 
examined the impact of propofol on thermoregulation identified that this 
medication markedly decreased the vasoconstriction and sweating thresholds. These 
findings explain why patients who receive propofol to induce general anaesthesia 
during surgery frequently develop unplanned hypothermia.42  
The evidence reviewed indicates that patients who receive sedation during CCL 
procedures may be at risk of developing unplanned hypothermia, due to the use of 
medications that impair thermoregulation. However, no studies were identified that 
examined the prevalence of unplanned hypothermia in this setting. Therefore, 
further research is required in order to determine whether or not these medications 
impair thermoregulation to the extent that patients become hypothermic in this 
context. In the absence of such research, the appropriateness of broad application of 
recommendations from guidelines for the promotion of normothermia during 
general anaesthesia to the CCL setting remains uncertain.43  
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Recommendations for practice 
While only a small number of studies fit the inclusion criteria set for this review, 
results from these studies indicate that unplanned hypothermia could potentially 
occur because the medications reduce the vasoconstriction and shivering thresholds. 
Therefore it is recommended clinicians should follow current guidelines for the 
prevention of unplanned perioperative hypothermia regarding frequent monitoring 
of body temperature and assessment for signs of hypothermia (shivering, 
piloerection and cold extremeities).43 Similarly, for all patients, skin exposure should 
be limited, passive warming initiated and the ambient room temperature maintained 
between 20 to 25°C.43 If hypothermia (<36°C) is identified, active warming should be 
applied.43 Active warming is recommended because passive warming strategies will 
only conserve, not add, heat content.9 However, no studies were identified that 
reported on the effectiveness of active warming devices in the CCL population. As 
such, no strong conclusions can be drawn for or against the use of any particular 
type of active warming device. Therefore, it is particularly important that all warming 
devices are used according to manufacturer instructions.43 
In current guidelines for the prevention of unplanned perioperative hypothermia, 
active warming is recommended for all patients undergoing procedures that are 
anticipated to last for longer than 30 minutes. The most commonly used sedation 
and analgesia medications used for sedation in the CCL are midazolam and 
fentanyl.4, 32 As outlined above, these medications do not impair thermoregulation 
to the extent of general and regional anaesthesia and studies have yet to investigate 
whether the administration of these medications, either in isolation or in 
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combination for the induction of sedation, is associated with unplanned 
hypothermia during CCL procedures. Moreover, frequent temperature monitoring 
during the peri-procedural period would facilitate prompt detection of hypothermia 
if it does occur. Thus, the use of active warming for normothermic patients whose 
procedure is anticipated to last for longer than 30 minutes is not indicated in the CCL 
setting if only sedative and analgesic medications are used. In contrast, evidence 
indicates that the short-acting anaesthetic agent propofol markedly decreases the 
vasoconstriction and shivering threshold.24, 25 For this reason, it is recommended 
that active warming should be applied during procedures that are expected to last 
for more than 30 minutes if propofol is one of the medications to be used for 
sedation during a procedure in the CCL.  
Recommendations for research 
Further research is required in order to provide stronger evidence for practice 
regarding the maintenance of normothermia during CCL procedures. Most important 
are preliminary studies investigating whether or not patients who receive sedation in 
the CCL inadvertently develop hypothermia. Implementation of the 
recommendations for practice from this article regarding frequent assessment as 
well as documentation of body temperature and thermal comfort would aid such 
research initiatives. If CCL patients who receive sedation are found to develop 
hypothermia during procedures, more in-depth examinations of risk factors and 
consequences should follow. For example, it has been identified that the elderly, 
females, patients with pre-operative systolic blood pressure less than 140mmHg are 
at higher risk of becoming hypothermic during general or neuraxial anaesthesia.43   
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Such investigations will need to be undertaken in the CCL setting in order to inform 
the development and evaluation of targeted strategies to prevent hypothermia from 
occurring. Considering the recent uptake of propofol for sedation in the CCL, also 
important is research into which specific active warming device is the most effective 
and practical in this context.39-41 
Conclusion 
Patients who inadvertently develop hypothermia during surgical procedures are at 
increased risk of major adverse cardiac events, wound complications, thrombotic as 
well as hemorrhagic complications and prolonged hospital stay.3 The evidence 
reviewed in this article indicates that patients who receive sedation in the CCL 
setting may also be at risk of developing unplanned hypothermia, due to the use of 
medications that impair thermoregulation.25, 27, 29 Therefore, further research is 
required regarding the maintenance of normothermia during the administration of 
sedation in the CCL.  
Page 16 of 23 
 
Table 1. Summary of included studies 
Author/s (Year) Design Sample Results 
Talke et al. (1997) Randomised, double-blind cross-over 
comparison of two doses of 
dexmedetomidine (drug 
administered by computer controlled 
infusion pump that targeted plasma 
concentration of dexmedetomidine 
of 0.3 and 0.6ng/mL) 
 9 males 
 Mean age 28 (Standard 
deviation 5 years) 
 Mean height 163cm 
(standard deviation 24cm) 
 Mean weight 74 kg 
(standard deviation 11kg) 
 Dexmedetomidine reduced the 
vasoconstriction threshold by 1.61 ± 0.80°C µg-
1mL 
 Dexmedetomidine reduced the shivering 
threshold by 1.61 ± 0.80°C µg-1mL 
 Interthreshold range increased to 0.5°C with 
low-dose dexmedetomidine and 1.3°C with 
high-dose dexmedetomidine 
Matsukawa et al. 
(1997) 
In simulated operating theatre 
conditions (minimally clothed, 
ambient room temperature of 22-
23°C), volunteers, in random order, 
received over 3 separate days: 1) no 
midazolam (control); 2) midazolam 
0.025mg/kg intramuscular injection; 
and 3) midazolam 0.075mg/kg 
intramuscular injection. 
 6 males  
 Mean height 169cm (160-
177) 
 Mean age 30 years (27-36) 
 Mean body temperature decreased with both 
doses of midazolam (Control day 
Mean=35.9[Range 35.6-36.3]; Midazolam 
0.025mg/kg Mean=35.7[Range 35.3-36.2]; 
Midazolam 0.075mg/kg Mean=35.7[range 35.1-
36.2]; p<0.01)  
 Thirty minutes after midazolam administration, 
mean core temperature of the high dose group 
decreased 0.6°C compared with 0.3°C for the 
low dose and 0.1°C for controls (p<0.01). 
 
Toyota et al. (2004) Randomised controlled trial. Prior to 
general anaesthesia, participants 
were randomised to control (C), 
premedication with midazolam 
0.04mg/kg intramuscular injection 
(M1) or premedication with 
midazolam 0.08mg/kg intramuscular 
injection (M2). 
 N=45 
 42% (n=19) male 
 Mean age: C=26 years 
(range 13-41); M1=23 (14-
44); M2=31 (Range 17-52)  
 Pre-induction core temperature was similar 
between the 3 groups (C=36.6°C; M1=36.5°C; 
M2=36.4°C) 
 While core temperature decreased in all groups 
following induction, there was a significantly 
greater decrease in temperature in C compared 
with M1 and M2 (p<0.05).  
 Fingertip blood flow was significantly less in C 
compared with M1 and M2 (p<0.05). 
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Kurz et al. (1995) In simulated operating theatre 
conditions (minimally clothed, 
ambient room temperature of 22-
23°C), volunteers, received over 2 
separate days: 1) no midazolam 
(control); 2) midazolam to reach a 
target concentration of 0.3mcg/mL. 
 N=8 females 
 Mean age 24 years (±3) 
 Height 172cm (±4cm) 
 Weight 64kg (±7kg) 
 Sweating threshold decreased 0.3°C with 
 midazolam administration: 37.3 ±0.2°C vs 37.0 
±0.3°C (P = 0.0004).  
 Vasoconstriction was observed at 36.3°C ±0.5°C 
compared with 37.1°C ±0.2°C in the control 
group (P = 0.0002).  
 Midazolam decreased the shivering threshold: 
35.9 ±0.3°C (Control day) vs 35.3 ±0.6°C 
(Midazolam day) (P = 0.03). 
 Interthreshold range increased from 0.2 ±0.1°C 
to 0.7 ±0.3°C (p=0.002). 
De Witte et al. (1998) In simulated operating theatre 
conditions (minimally clothed, 
ambient room temperature of 22-
23°C), volunteers, received in oral 
form over 4 separate days: 1st day) no 
medication (control); 2nd day) 
tramadol 125mg; 3rd day) tramadol 
250mg; and 4th day) tramadol 250mg 
with naloxone (1.6mg intravenously 
over 15 minutes followed by a 
maintenance infusion at a rate of 
1mg/hour). 
 N=8 males 
 Mean age 30 years (±6 
years) 
 Height 174cm (±6cm) 
 Weight 72kg (±8kg) 
 Tramadol decreased sweating threshold by 1.03 
±0.67°C µg-1mL (r2=0.90±0.12). 
 Tramadol decreased vasoconstriction threshold 
by 3.0 ±4.0 °C µg-1mL (r2=0.94±0.98) 
 Tramadol decreased the shivering threshold by 
4.2±4.0 °C µg-1mL (r2=0.98±0.98) 
 The interthreshold increased from 0.3±0.4°C to 
0.7±0.6°C during tramadol administration 
(p=0.04) 
Ikeda et al. (1997) Two separate studies were reported 
in this article, focusing on alfentanil 
and meperidine. 
Alfentanil study: 
In simulated operating theatre 
Alfentanil study: 
N=8  
No demographic 
characteristics reported 
 
Alfentanil study 
 Alfentanil increased sweating threshold  0.021 
±0.016°C µg-1mL (r2=0.92±0.06). 
 Alfentanil decreased vasoconstriction threshold  
0.075±0.067 °C µg-1mL (r2=0.92±0.07) 
 Tramadol decreased the shivering threshold -
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conditions (minimally clothed, 
ambient room temperature of 22-
23°C), volunteers, received over 3 
separate days: 1) no medication 
(control); 2) alfentanil to reach a 
target concentration of 100ng/mL; 
and 3) alfentanil to reach a target 
concentration of 300ng/mL. 
Meperidine study: 
In simulated operating theatre 
conditions (minimally clothed, 
ambient room temperature of 22-
23°C), volunteers, received over 3 
separate days: 1) no medication 
(control); 2) meperidine to reach a 
target concentration of 0.6mcg/mL; 
and 3) meperidine to reach a target 
concentration of 1.8mcg/mL. 
 
Meperidine study: 
N=9 
No demographic 
characteristics reported 
 
0.063±0.037 °C µg-1mL (r2=0.98±0.04) 
Meperidine study 
 Interthreshold range increased from 0.4 
±0.18°C on the control day to 1.1 ±0.34°C when 
the target total plasma meperidine 
concentration was 0.6 mcg/ml, and to 1.9 ± 
0.7°C when the target was 1.8 mcg/ml 
 
Kurz et al. (1997) In simulated operating theatre 
conditions (minimally clothed, 
ambient room temperature of 22-
23°C), volunteers, received in random 
order over 3 separate days: 1) no 
medication (control); 2) meperidine 
to reach a target concentration of 
0.6mcg/mL; and 3) meperidine to 
reach a target concentration of 
 N=9 
 Mean age 31 years (±6 
years) 
 Height 177cm (±4cm) 
 Weight 72kg (±6kg) 
 Meperdine decreased vasoconstriction 
threshold by 3.3±1.5°C µg-1mL (r2=0.92±0.08). 
 Meperdine decreased shivering threshold by 
6.1±3.0°C µg-1mL (r2=0.97±0.05). 
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1.8mcg/mL. 
Matsukawa et al. 
(1995) 
In simulated operating theatre 
conditions (minimally clothed, 
ambient room temperature of 22-
23°C), volunteers, received in random 
order over 4 separate days: 1st day) 
no medication (control); 2nd day) a 
target blood propofol concentration 
of 2mcg/mL; 3rd day) a target blood 
propofol concentration of 4mcg/mL; 
and 4th day) a target blood propofol 
concentration of 8mcg/mL. 
 N=4 
 Mean age 30 years (±7 
years) 
 Height 175cm (±6cm) 
 Weight 78kg (±10kg) 
 Propofol decreased vasoconstriction threshold  
-0.6±0.1°C µg-1mL (r2=0.98±0.02). 
 Propofol decreased shivering threshold by 
0.7±0.1°C µg-1mL (r2=0.95±0.05). 
 Interthreshold range increased by 0.7±0.1°C µg-
1mL during propofol administration 
 
Leslie et al. (1994) In simulated operating theatre 
conditions (minimally clothed, 
ambient room temperature of 22-
23°C), volunteers, received in random 
order over 3 separate days: 1st day) 
no medication (control); 2nd day) a 
target blood propofol concentration 
of 2mcg/mL; 3rd day) a target blood 
propofol concentration of 4mcg/mL. 
on each day, epidural anaesthesia 
was induced using 2% 2-
chlorprocaine. 
 N=6 
 Mean age 31 years (±6 
years) 
 Height 182cm (±4cm) 
Weight 80kg (±6kg) 
 Propofol decreased vasoconstriction threshold -
0.53±0.34°C µg-1mL (r2=0.98±0.04). 
 Propofol had little effect on the sweating 
threshold. 
 Interthreshold range increased by 0.49±0.39°C 
µg-1mL during propofol administration 
 
Legend: °C = degrees celcius
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